Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma

URN to cite this document:: urn:nbn:de:bvb:355-epub-506024
DOI to cite this document:: 10.5283/epub.50602

Brill, Richard ; Uller, Wibke ; Huf, Veronika ; Müller‐Wille, René ; Schmid, Irene ; Pohl, Alexandra ; Häberle, Beate ; Perkowski, Sybille ; Funke, Katrin ; Till, Anne‐Marie ; Lauten, Melchior

; Neumann, Jacob ; Güttel, Christian ; Heid, Esther ; Ziermann, Franziska ; Schmid, Axel ; Hüsemann, Dieter ; Meyer, Lutz ; Sporns, Peter B. ; Schinner, Regina ; Schmidt, Vanessa F.

; Ricke, Jens ; Rössler, Jochen ; Kapp, Friedrich G.

; Wohlgemuth, Walter A. ; Wildgruber, Moritz

License: Creative Commons Attribution 4.0
PDF - Published Version
(904kB)

Date of publication of this fulltext: 11 Oct 2021 13:10

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor in children, which can be accompanied by life-threatening thrombocytopenia, referred to as Kasabach-Merritt phenomenon (KMP). The mTOR inhibitor sirolimus is emerging as targeted therapy in KHE. As the sirolimus effect on KHE occurs only after several weeks, we aimed to evaluate whether additional transarterial embolization is of ...